{"id":955432,"date":"2026-04-28T09:05:02","date_gmt":"2026-04-28T13:05:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/"},"modified":"2026-04-28T09:05:02","modified_gmt":"2026-04-28T13:05:02","slug":"veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/","title":{"rendered":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers"},"content":{"rendered":"

<\/p>\n

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers<\/b><\/p>\n

Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Veracyte, Inc<\/a>.<\/a> (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in bladder cancer and feature national-scale real\u2011world data analyses in prostate cancer that demonstrate how Decipher Prostate informs treatment decisions. Additional real\u2011world data from the Decipher Genomics Research for Intelligent Discovery (GRID) research tool continues to fuel the flywheel of evidence in urologic cancers through ongoing research studies.<\/p>\n

\n\u201cThese studies underscore the power of Veracyte\u2019s Diagnostics Platform to generate clinically meaningful evidence at scale,\u201d said Elai Davicioni, Ph.D., Veracyte\u2019s medical director, Urology. \u201cWith more than a decade of data in our Decipher GRID tool, we are accelerating research to drive new discoveries that help clinicians better personalize care and improve outcomes for patients.\u201d<\/p>\n

\nAt this year\u2019s meeting, during Bladder Cancer Awareness month in May, several studies will highlight the clinical relevance of molecular subtyping in bladder cancer using the Decipher Bladder test, including its role in guiding treatment decisions and predicting outcomes. Key presentations include:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Title:<\/i><\/p>\n<\/td>\n

\n

Molecular Characterization and a Showcase Clinical Study on Treatment De-escalation for Luminal Favorable Muscle-Invasive Bladder Cancer<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nMelissa Moran, DO, Rutgers Robert Wood Johnson University Hospital<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPoster<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nIP35-15<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

Saturday, May 16, 2026, 9:30 \u2013 11:30 AM ET<\/td>\n<\/tr>\n
\n

Location:<\/i><\/p>\n<\/td>\n

147A<\/td>\n<\/tr>\n
\n\u00a0<\/td>\n<\/tr>\n
\n

Title:<\/i><\/p>\n<\/td>\n

\n

Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immunotherapy for Muscle-Invasive Bladder Cancer (Biomarker analyses from NURE-combo & BLASST-01 phase 2 trials)<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nJoep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPoster<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nIP47-06<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\nSaturday, May 16, 2026, 3:30 – 5:30 PM ET<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n147A<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

Non-Luminal Subtype is Associated with Worse Overall Survival in High-Risk Non-Muscle Invasive Bladder Cancer Patients – Biomarker Results from The Bladder Cancer Prognosis Programme<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nJoep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPoster<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nIP47-07<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\nSaturday, May 16, 2026, 3:30 – 5:30 PM ET<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n147A<\/p>\n<\/td>\n<\/tr>\n

\n\u00a0<\/td>\n<\/tr>\n
\n

Title:<\/i><\/p>\n<\/td>\n

Examining the impact of TGF-\u03b2 activity on fibroblast infiltration and immune exclusion in muscle-invasive bladder cancer<\/a><\/td>\n<\/tr>\n
\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nShilpa Gupta, M.D., Cleveland Clinic Foundation<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPodium presentation<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nPD15-10<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\nSaturday, May 16, 2026, 4:42 – 4:50 PM ET<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n206<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTogether, these studies demonstrate how molecular subtyping can help refine risk stratification, identify patient subsets with differing clinical outcomes, and deepen understanding of tumor biology.<\/p>\n

\n\u201cThese data suggest that molecular subtyping using Decipher Bladder may help identify patients who are more likely to achieve downstaging and complete responses to neoadjuvant chemo-immunotherapy,\u201d said Shilpa Gupta, M.D., GU Oncologist, Cleveland Clinic. \u201cBy better understanding tumor biology upfront, we have the potential to more precisely select therapies and, ultimately, improve outcomes while avoiding unnecessary treatment for patients with muscle-invasive bladder cancer.\u201d<\/p>\n

Unlocking Insights with Real-World Evidence from Decipher Prostate and the GRID Database<\/b><\/p>\n

\nLarge\u2011scale analyses using Decipher genomic data alongside real\u2011world clinical datasets provide insights into how prostate cancer management is being shaped across diverse patient populations, helping clinicians more confidently tailor treatment decisions. These efforts also support ongoing research to deepen understanding of prostate cancer biology and inform personalized care. Key presentations include:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Title:<\/i><\/p>\n<\/td>\n

\n

Association of Biopsy-Based Genomic Classifier and Initial Treatment for Prostate Cancer: Results from a National Clinical\u2013Genomic Linkage<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nMichael Leapman, M.D., Department of Urology, Yale School of Medicine<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPoster<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nIP31-20<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\nSaturday, May 16, 2026, 9:30 – 11:30 AM ET<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i>\u00a0<\/p>\n<\/td>\n

\n

\n145AB<\/p>\n<\/td>\n<\/tr>\n

\n\u00a0<\/td>\n<\/tr>\n
\n

Title:<\/i><\/p>\n<\/td>\n

\n

Genomic Classifier Results and Use of Post-Prostatectomy Treatment Among a National Cohort of Patients with Prostate Cancer<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nMichael Leapman, M.D., Department of Urology, Yale School of Medicine<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPoster<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nIP62-22<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\nSunday, May 17, 2026, 1:00 – 3:00 PM ET<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n146A<\/p>\n<\/td>\n<\/tr>\n

\n\u00a0<\/td>\n<\/tr>\n
\n

Title:<\/i><\/p>\n<\/td>\n

\n

Correlative analysis of the expression of two PET imaging targets, PSMA and ACP3, in a large radical prostatectomy cohort from the Decipher GRID registry<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\nMohammed Shahait, M.D., UCI Urology<\/p>\n<\/td>\n<\/tr>\n

\n

Format:<\/i><\/p>\n<\/td>\n

\n

\nPoster<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\nIP62-05<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\nSunday, May 17, 2026, 1:00 – 3:00 PM ET<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n146A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u201cDecipher GRID enables analyses that were not previously possible,\u201d said Dr. Michael Leapman Associate Professor of Urology, Yale School of Medicine. \u201cOur findings suggest that genomic information from Decipher Prostate may help refine treatment decision-making and move care toward more precise, individualized management of prostate cancer.\u201d<\/p>\n

\nMore information about Veracyte\u2019s presence at AUA 2026 can be found at the company\u2019s booth #3405 and on Veracyte\u2019s website here<\/a>.<\/p>\n

About Decipher Prostate<\/b><\/p>\n

\nThe Decipher Prostate Genomic Classifier<\/a> is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients\u2019 care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients. It is the only gene expression test to achieve \u201cLevel 1B\u201d evidence status and inclusion in the risk-stratification table in the most recent NCCN\u00ae Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here<\/a>.<\/p>\n

About Decipher Bladder<\/b><\/p>\n

\nThe Decipher Bladder Genomic Classifier<\/a> is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and\/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here<\/a>.<\/p>\n

About Decipher GRID<\/b><\/p>\n

\nThe Decipher GRID database<\/a> includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More information about Decipher GRID can be found here<\/a>.<\/p>\n

About Veracyte<\/b><\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform<\/a> delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development<\/a>. For more information, please visit www.veracyte.com<\/a> or follow us on LinkedIn<\/a> or X<\/a> (Twitter).<\/p>\n

Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements, including, but not limited to our statements related to regarding the potential clinical utility, impact, and benefits of Veracyte\u2019s Decipher Bladder and Prostate tests; how molecular subtyping can help inform treatment decisions, improve patient outcomes, or avoid unnecessary treatment for patients; the role of real\u2011world data and the Decipher Genomics Research for Intelligent Discovery (GRID) platform in advancing research or enabling new discoveries; and the potential impact of Veracyte\u2019s diagnostic solutions.. Forward-looking statements can be identified by words such as: \u201cappears,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cshould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cenable,\u201d \u201cpositioned,\u201d \u201coffers,\u201d \u201cdesigned,\u201d “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed on February 26, 2026 and our subsequent Quarterly Reports on Form 10-Q. Copies of these documents, when available, may be found in the Investors section of our website at https:\/\/investor.veracyte.com<\/a>. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.<\/p>\n

\n*National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260428470902\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
Kelly Gura
\n
investors@veracyte.com<\/a><\/p>\n

Media:
\n<\/b>
Molly Cornbleet
\n
media@veracyte.com<\/a><\/p>\n

KEYWORDS:<\/b> California District of Columbia United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Oncology General Health Health Genetics Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in … <\/p>\n

Continue reading “Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955432","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVeracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in … Continue reading "Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T13:05:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers\",\"datePublished\":\"2026-04-28T13:05:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/\"},\"wordCount\":1564,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/\",\"name\":\"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-28T13:05:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Market Newsdesk","og_description":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in … Continue reading \"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-28T13:05:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers","datePublished":"2026-04-28T13:05:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/"},"wordCount":1564,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/","name":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-28T13:05:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260428470902r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955432"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955432\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}